Inappropriate secretion of TSH was first described in 1960 in a patient with evidence of
hyperthyroidism and expanded sella on imaging. It was later found that a type of pituitary …

Acromegaly is a chronic disease with an increased mortality in case of persistently active
disease. The treatment of acromegaly is mainly based on the surgical resection of the GH …

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that present
many clinical features secreting peptides and neuroamines that cause distinct clinical …

Objectives: To evaluate somatostatin receptor 2A (SSTR2A) and dopamine receptor 2 (DR2)
protein expression in somatotropinomas and to relate it to response to somatostatin …

Somatostatin (SS) and dopamine (DA) receptors have been highlighted as two critical
regulators in the negative control of hormonal secretion in a wide group of human endocrine …

Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These
tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of …

The most recent World Health Organization classification of renal neoplasms encompassed
nearly 50 distinctive renal neoplasms. Different histological subtypes have different clinical …

Introduction• The somatostatin receptor as a GPCR• Anti‐tumour effects of somatostatin•
Post‐receptor signalling pathways‐Phosphotyrosine phosphatases and their action on …

Context: Pituitary adenomas can cause specific syndromes due to hormone excess and/or
determine sellar mass symptoms. Pituitary cell growth can sometimes be influenced by …

Endogenous somatostatin shows anti-secretory effects in both physiological and
pathological settings, as well as inhibitory activity on cell growth. Since somatostatin is not …